MedTrace Logo

Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors

NCT00002463 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2013-02-18

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.

Conditions

Interventions

DRUG

MOPP Regimen

Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)

DRUG

Leucovorin Calcium

DRUG

Mechlorethamine Hydrochloride

DRUG

Methotrexate

DRUG

Prednisone

DRUG

Procarbazine Hydrochloride

DRUG

Vincristine Sulfate

PROCEDURE

Conventional Surgery

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Joann Ater, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1989-02-28
Primary Completion
2007-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002463 on ClinicalTrials.gov